Treatment of symptomatic chronic subdural hematoma with dexamethasone may worsen outcomes compared with placebo.
Among pediatric patients with congenital fibrinogen deficiency, the administration of human fibrinogen concentrate may be efficacious for on-demand treatment and surgical prophylaxis.
Predicting bleeding during cardiopulmonary bypass is complex and not captured by tests, including measuring von Willebrand factor interaction.
Patients with hemophilia A who are treated with emicizumab may safely receive additional hemostatic agents when undergoing surgery.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Research presented at the 2020 annual meeting of the American Society of Hematology reveals semiautomatic densitometric analysis of von Willebrand factor multimers to have excellent accuracy in clinical practice.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
The use of PCCs may benefit patients who experience bleeding after cardiopulmonary bypass surgery by decreasing RBC and platelet transfusions.
In minor procedures, coagulation differences may not be clinically significant to determine bleeding or thrombotic periprocedure complication risks.
A team of investigators provided a real-world understanding of apixaban or rivaroxaban-linked acute bleeding events in patients receiving aPCC.
According to survey results, patients with hemophilia appear to be satisfied with care received at US hemophilia treatment centers.
Researchers compared quality of life and work-related function in patients with hemophilia A with patients with osteoarthritis and the general population.
Epidural analgesia in pregnant women with VWD type 1 appears to be safe with VWF and factor VIII levels of 80% or more in the third trimester.
For patients with severe hemophilia A, N8-GP was safe and efficacious according to the results of the pathfinder clinical programs.
Study results suggest that TEG and turbidimetry measure clot formation in separate ways and should be used synergistically.
Researchers developed a novel population pharmacokinetics model of recombinant von Willebrand factor in patients with VWD or severe hemophilia A.
Rurioctocog alfa pegol targeting FVIII troughs benefits patients with severe hemophilia A, according to research presented at the THSNA 2020 virtual meeting.
In a comprehensive evaluation, investigators assessed the efficacy and safety of 4F-PCC for oral fXa inhibitor–related emergent bleeding.
BIVV001, a novel fusion protein, has longer half-life than recombinant factor VIII products and may be a safe therapy for hemophilia A.
Investigators assessed whether there was a link between low bone mineral density, 25(OH)D concentrations, and bone turnover markers in hemophilia.
Inadvertent administration may result in serious adverse events.
ABO blood group has been associated with cardiovascular disease and thrombotic risk; however, influences on hemostasis are still not well understood.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
There is a need for novel, effective treatments for pediatric patients with hemophilia A with FVIII inhibitors to reduce annualized bleeding rates.
Investigators studied the frequency and risk factors linked to wound healing complications after elective orthopedic surgery in patients with hemophilia.
A team of investigators sought to determine whether endotheliopathy is involved in COVID-19–associated coagulopathy pathogenesis.
Investigators aimed to improve the understanding of the epidemiologic, clinical, and laboratory findings of cold agglutinin disease.
In addition to well-described platelet defects in gray platelet syndrome, immune defects, such as abnormal cells also exist.
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
In about 10% of pregnancies in which the mother has a congenital bleeding disorder, recommended fetal precautionary measures may influence the mode of delivery.
Researchers assessed whether hemophilia A disease registry could be used instead of clinical studies to determine orphan drug safety in pediatric patients.
There was a median bleeding score of 21 among patients with Glanzmann thrombasthenia, 9 in Bernard-Soulier syndrome, 10 in dense granule deficiency, 7 in ADP pathway defect, 8 in TxA2 pathway defect, 6 in isolated thrombocytopenia, and 8 in complex abnormalities.
Genetic mutations associated with the heterogeneity of hemophilia B Leyden may also be linked to mechanisms that increase factor IX levels with age.
VTE-BLEED prognostic scores did not accurately identify patients with VTE who were at high risk of bleeding events.
New developments in lab assays have allowed for more specialized assessments of VWD activity, leading to better diagnoses and various treatment options.
The percentage of discordance in onsite and off-site laboratory testing of von Willebrand disease remains high.
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
The exact number of hemophilia cases are unknown and estimates of the size and characteristics of the US hemophilia population are needed for healthcare planning and resource needs assessment.
Approximately 30% of patients with hemophilia are considered sporadic cases, causing a challenge when determining carrier status and disease transmission risk to offspring.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Identifying hemophilia A in women and girls with factor VIII deficiency with bleeding events using healthcare claims still remains a challenge.
Researchers assessed 136 patients with VWD in Iran over 13 years to characterize clinical and molecular patterns associated with the disease.
The FDA has approved Sevenfact (coagulation factor VIIa [recombinant]-jncw; LFB Biotechnologies) for the treatment and control of bleeding episodes occurring in patients aged ≥12 years with hemophilia A or B with inhibitors.
The authors stated, however, that genetic screening should be used with caution in children.
Neither factor VIII clotting activity nor factor VIII antigens were significantly different for any blood group in patients with nonsevere hemophilia A.
Researchers found that exposure to opioids in patients with hemophilia may be underreported in the American Thrombosis and Hemostasis Network dataset.
Patients who experienced major adverse cardiovascular events reported higher von Willebrand factor plasma levels compared with patients in the control cohort.
Patients with hemophilia were found to experience worse general health but higher levels of psychological well-being compared with individuals in the control arm.
Novo Nordisk announced the launch of Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei) for the treatment of adult and pediatric patients with hemophilia A for routine prophylaxis.
Of patients who received cefoperazone-sulbactam, 9.2% reported a coagulation disorder and 15.7% reported a decrease in platelet count.